Himadri Speciality Chemical: Monitoring Agency Report for Q4 FY26 Shows No Deviation in Fund Utilization
Himadri Speciality Chemical's Monitoring Agency Report for Q4 FY26 confirms no deviation in fund utilization from its preferential issue of warrants amounting to ₹341.8172 crore. Capital expenditure utilization stands at ₹146.57 crore, and general corporate purposes utilization is ₹82.87 crore.
This is a routine monitoring report confirming compliance with the utilization of previously raised funds. It does not introduce new material information that would significantly impact the company's stock or operations.
The report indicates no deviation in the utilization of funds raised through the preferential issue, which is a positive sign for compliance and financial management.
Himadri Speciality Chemical Limited (HSCL) has submitted its Monitoring Agency Report for the quarter ended March 31, 2026. The report, issued by ICRA Limited, confirms that the utilization of proceeds from the Preferential Issue of Warrants is in line with the objects of the issue, with no deviation observed.
The total issue size was ₹341.8172 crore, comprising 108,17,000 warrants issued at ₹316 each. The allocated amounts were ₹256.8172 crore for Capital Expenditure and ₹85 crore for General Corporate Purposes.
During the fourth quarter of FY2026, the company utilized ₹78.0337 crore for Capital Expenditure, bringing the total utilized amount to ₹146.5708 crore against the proposed ₹256.8172 crore. The unutilized amount for Capital Expenditure stands at ₹110.2464 crore.
For General Corporate Purposes, ₹82.8660 crore was utilized during the quarter, bringing the total utilized amount to ₹82.8660 crore against the proposed ₹85 crore. The unutilized amount for General Corporate Purposes is ₹2.1340 crore. The total unutilized proceeds as of March 31, 2026, amount to ₹112.3804 crore, primarily invested in mutual funds (₹111.7257 crore) and a cash credit account (₹0.6547 crore).
The report also states that the utilization of proceeds for both Capital Expenditure and General Corporate Purposes is on schedule, with the expected utilization within 12 months from the receipt of respective amounts.
What to do with a filing like this
Himadri Speciality Chemical Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Himadri Speciality Chemical Limited. Read the original for the full detail.